Since these 2 groups had very similar Rai stages, ALCs, serum β2M levels, and IVIg prophylaxis requirements (Fig 4B and Table 2), these data indicated that the inferior NAb responses in CLL patients immunized with BNT162b2 were not a consequence of differences in disease progression. Here, B2M is linked to B-cell chronic lymphocytic leukemia.